Olanzapine dose for people with schizophrenia

Clozapine Induces an Acute Proinflammatory Response That Is Attenuated by Inhibition of Inflammasome Signaling: Implications for Idiosyncratic Drug-Induced Agranulocytosis

“…Olanzapine and fluperlapine have structures similar to clozapine, where the former forms an analogous reactive nitrenium ion but is not associated with IDIAG ( Gardner et al , 1998b ), and the latter forms a reactive quinone imine but is not approved for clinical use due to concerns of potential IDR cases during development ( Lai et al , 2000 ). One hypothesis to explain the increased IDIAG risk for clozapine compared with olanzapine is dose, because the therapeutic dose of olanzapine for schizophrenic patients is around 10–15 mg/day ( Latifeh et al , 2019 ), compared with typical clozapine regimens of up to 600 mg/day ( Subramanian et al , 2017 ). It is unlikely that dose is the only factor as described previously, in our rat model, we found that an equimolar dose of olanzapine to clozapine did not trigger the same increase in peripheral blood neutrophils ( Ng et al , 2014 ).…”

Classification of all pharmacological interventions tested in trials relevant to people with schizophrenia: A study‐based analysis

“…Up until today (28 February 2020), this classification effort has detected new comparisons for review titles, new classes of drugs and new qualifiers from existing RCTs. These discoveries were assessed by Cochrane editors and led to start and, in some cases, accomplishment of at least 14 Cochrane reviews: six on qualifiers (Abbas et al, 2017; Hanafi et al, 2017; Latifeh et al, 2019; Turk, Alkhatib, et al, 2017; Turk, Zuhri Yafi, et al, 2017; Turkmani et al, 2019), one on a class of drugs (Karl et al, 2018) and nine on comparing two drugs (Bazrafshan et al, 2015; Chattopadhyay et al, 2016; Eslami Shahrbabaki et al, 2018; Ibragimov et al, 2019; Mazhari et al, 2017; Nikvarz et al, 2017; Nur & Adams, 2016; Schmidt et al, 2019; Zare & Bazrafshan, 2017).…”